{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:56:53Z","timestamp":1776232613196,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sporadic Creutzfeldt-Jakob disease (sCJD), the most common human prion disease, is a fatal neurodegenerative disease with currently no treatment options. Stem cell therapy for neurodegenerative diseases is emerging as a possible treatment option. However, while there are a few clinical trials for other neurodegenerative disorders such as Parkinson\u2019s disease, prion disease cell therapy research has so far been confined to animal models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Here, we use a novel approach to study cell therapies in sCJD using a human cerebral organoid model. Cerebral organoids can be infected with sCJD prions allowing us to assess how neural precursor cell (NPC) therapy impacts the progression of sCJD. After 90 days of sCJD or mock infection, organoids were either seeded with NPCs or left unseeded and monitored for cellular composition changes, prion infection parameters and neuroelectrophysiological function at 180 days post-infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our results showed NPCs integrated into organoids leading to an increase in neuronal markers and changes in cell signaling irrespective of sCJD infection. Although a small, but significant, decrease in protease-resistant PrP deposition was observed in the CJD-infected organoids that received the NPCs, other disease-associated parameters showed minimal changes. However, the NPCs had a beneficial impact on organoid function following infection. sCJD infection caused reduction in neuronal spike rate and mean burst spike rate, indicative of reduced action potentials. NPC seeding restored these electrophysiological parameters to the uninfected control level.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Together with the previous animal studies, our results support that cell therapy may have some functional benefit for the treatment of human prion diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13287-023-03591-2","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:02:11Z","timestamp":1701734531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Neural cell engraftment therapy for sporadic Creutzfeldt-Jakob disease restores neuroelectrophysiological parameters in a cerebral organoid model"],"prefix":"10.1186","volume":"14","author":[{"given":"Katie","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simote T.","family":"Foliaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Race","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley R.","family":"Groveman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-1149","authenticated-orcid":false,"given":"Cathryn L.","family":"Haigh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"issue":"8","key":"3591_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1055\/s-0042-1755341","volume":"80","author":"LHL Miranda","year":"2022","unstructured":"Miranda LHL, Oliveira A, Carvalho DM, Souza GMF, Magalh\u00e3es JGM, J\u00fanior JAC, et al. Systematic review of pharmacological management in Creutzfeldt-Jakob disease: no options so far? Arq Neuropsiquiatr. 2022;80(8):837\u201344.","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"3591_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/jnnp-2016-313541","volume":"88","author":"D Varges","year":"2017","unstructured":"Varges D, Manthey H, Heinemann U, Ponto C, Schmitz M, Schulz-Schaeffer WJ, et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry. 2017;88(2):119\u201325.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"3591_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/jnnp-2013-305590","volume":"85","author":"PK Newman","year":"2014","unstructured":"Newman PK, Todd NV, Scoones D, Mead S, Knight RS, Will RG, et al. Postmortem findings in a case of variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulfate. J Neurol Neurosurg Psychiatry. 2014;85(8):921\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"3591_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1468-1331.2008.02108.x","volume":"15","author":"I Bone","year":"2008","unstructured":"Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol. 2008;15(5):458\u201364.","journal-title":"Eur J Neurol"},{"issue":"6","key":"3591_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00701-006-0772-y","volume":"148","author":"IR Whittle","year":"2006","unstructured":"Whittle IR, Knight RS, Will RG. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. Acta Neurochir (Wien). 2006;148(6):677\u20139.","journal-title":"Acta Neurochir (Wien)."},{"issue":"2","key":"3591_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","volume":"13","author":"S Ha\u00efk","year":"2014","unstructured":"Ha\u00efk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(2):150\u20138.","journal-title":"Lancet Neurol"},{"issue":"6","key":"3591_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.surneu.2005.03.035","volume":"64","author":"JF Mart\u00ednez-Lage","year":"2005","unstructured":"Mart\u00ednez-Lage JF, R\u00e1bano A, Bermejo J, Mart\u00ednez P\u00e9rez M, Guerrero MC, Contreras MA, et al. Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg Neurol. 2005;64(6):542\u20135.","journal-title":"Surg Neurol."},{"issue":"23","key":"3591_CR8","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1212\/WNL.0b013e3182a9f3b4","volume":"81","author":"MD Geschwind","year":"2013","unstructured":"Geschwind MD, Kuo AL, Wong KS, Haman A, Devereux G, Raudabaugh BJ, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013;81(23):2015\u201323.","journal-title":"Neurology"},{"issue":"4","key":"3591_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","volume":"8","author":"J Collinge","year":"2009","unstructured":"Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009;8(4):334\u201344.","journal-title":"Lancet Neurol"},{"issue":"12","key":"3591_CR10","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1212\/01.WNL.0000148596.15681.4D","volume":"63","author":"S Ha\u00efk","year":"2004","unstructured":"Ha\u00efk S, Brandel JP, Salomon D, Sazdovitch V, Delasnerie-Laupr\u00eatre N, Laplanche JL, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology. 2004;63(12):2413\u20135.","journal-title":"Neurology"},{"issue":"3","key":"3591_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000076350","volume":"17","author":"M Nakajima","year":"2004","unstructured":"Nakajima M, Yamada T, Kusuhara T, Furukawa H, Takahashi M, Yamauchi A, et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord. 2004;17(3):158\u201363.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"3591_CR12","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1212\/01.WNL.0000113764.35026.EF","volume":"62","author":"M Otto","year":"2004","unstructured":"Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology. 2004;62(5):714\u20138.","journal-title":"Neurology"},{"issue":"20","key":"3591_CR13","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, et al. Personalized iPSC-derived dopamine progenitor cells for parkinson\u2019s disease. N Engl J Med. 2020;382(20):1926\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"3591_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/00001756-200101220-00023","volume":"12","author":"KL Brown","year":"2001","unstructured":"Brown KL, Brown J, Ritchie DL, Sales J, Fraser JR. Fetal cell grafts provide long-term protection against scrapie induced neuronal loss. NeuroReport. 2001;12(1):77\u201382.","journal-title":"NeuroReport"},{"issue":"11","key":"3591_CR15","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1128\/JVI.00165-09","volume":"83","author":"CH Song","year":"2009","unstructured":"Song CH, Honmou O, Ohsawa N, Nakamura K, Hamada H, Furuoka H, et al. Effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prions. J Virol. 2009;83(11):5918\u201327.","journal-title":"J Virol"},{"issue":"10","key":"3591_CR16","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1099\/jgv.0.000907","volume":"98","author":"Z Shan","year":"2017","unstructured":"Shan Z, Hirai Y, Nakayama M, Hayashi R, Yamasaki T, Hasebe R, et al. Therapeutic effect of autologous compact bone-derived mesenchymal stem cell transplantation on prion disease. J Gen Virol. 2017;98(10):2615\u201327.","journal-title":"J Gen Virol"},{"issue":"7","key":"3591_CR17","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/infdis\/jir484","volume":"204","author":"A Rela\u00f1o-Gin\u00e9s","year":"2011","unstructured":"Rela\u00f1o-Gin\u00e9s A, Lehmann S, Bencsik A, Herva ME, Torres JM, Crozet CA. Stem cell therapy extends incubation and survival time in prion-infected mice in a time window-dependant manner. J Infect Dis. 2011;204(7):1038\u201345.","journal-title":"J Infect Dis"},{"key":"3591_CR18","doi-asserted-by":"publisher","first-page":"1158408","DOI":"10.3389\/fnins.2023.1158408","volume":"17","author":"AJD Hay","year":"2023","unstructured":"Hay AJD, Latham AS, Mumford G, Hines AD, Risen S, Gordon E, et al. Intranasally delivered mesenchymal stromal cells decrease glial inflammation early in prion disease. Front Neurosci. 2023;17:1158408.","journal-title":"Front Neurosci"},{"key":"3591_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.neurobiolaging.2020.07.030","volume":"95","author":"K Frid","year":"2020","unstructured":"Frid K, Binyamin O, Usman A, Gabizon R. Delay of gCJD aggravation in sick TgMHu2ME199K mice by combining NPC transplantation and Nano-PSO administration. Neurobiol Aging. 2020;95:231\u20139.","journal-title":"Neurobiol Aging"},{"key":"3591_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.neurobiolaging.2018.01.004","volume":"65","author":"K Frid","year":"2018","unstructured":"Frid K, Binyamin O, Fainstein N, Keller G, Ben-Hur T, Gabizon R. Autologous neural progenitor cell transplantation into newborn mice modeling for E200K genetic prion disease delays disease progression. Neurobiol Aging. 2018;65:192\u2013200.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"3591_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40478-019-0742-2","volume":"7","author":"BR Groveman","year":"2019","unstructured":"Groveman BR, Foliaki ST, Orru CD, Zanusso G, Carroll JA, Race B, et al. Sporadic Creutzfeldt-Jakob disease prion infection of human cerebral organoids. Acta Neuropathol Commun. 2019;7(1):90.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"3591_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40478-023-01512-1","volume":"11","author":"BR Groveman","year":"2023","unstructured":"Groveman BR, Race B, Foliaki ST, Williams K, Hughson AG, Baune C, et al. Sporadic Creutzfeldt-Jakob disease infected human cerebral organoids retain the original human brain subtype features following transmission to humanized transgenic mice. Acta Neuropathol Commun. 2023;11(1):28.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"3591_CR23","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1038\/s41598-021-84689-6","volume":"11","author":"BR Groveman","year":"2021","unstructured":"Groveman BR, Ferreira NC, Foliaki ST, Walters RO, Winkler CW, Race B, et al. Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt-Jakob disease. Sci Rep. 2021;11(1):5165.","journal-title":"Sci Rep"},{"issue":"1","key":"3591_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13041-021-00864-w","volume":"14","author":"ST Foliaki","year":"2021","unstructured":"Foliaki ST, Schwarz B, Groveman BR, Walters RO, Ferreira NC, Orr\u00f9 CD, et al. Neuronal excitatory-to-inhibitory balance is altered in cerebral organoid models of genetic neurological diseases. Mol Brain. 2021;14(1):156.","journal-title":"Mol Brain"},{"issue":"1","key":"3591_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1010565","volume":"19","author":"ST Foliaki","year":"2023","unstructured":"Foliaki ST, Smith A, Schwarz B, Bohrnsen E, Bosio CM, Williams K, et al. Altered energy metabolism in Fatal Familial Insomnia cerebral organoids is associated with astrogliosis and neuronal dysfunction. PLoS Genet. 2023;19(1): e1010565.","journal-title":"PLoS Genet"},{"issue":"12","key":"3591_CR26","doi-asserted-by":"publisher","first-page":"11247","DOI":"10.1074\/jbc.M407006200","volume":"280","author":"C F\u00e9raudet","year":"2005","unstructured":"F\u00e9raudet C, Morel N, Simon S, Volland H, Frobert Y, Cr\u00e9minon C, et al. Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J Biol Chem. 2005;280(12):11247\u201358.","journal-title":"J Biol Chem"},{"issue":"2 Pt 1","key":"3591_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1006\/exnr.1997.6503","volume":"145","author":"C Lundberg","year":"1997","unstructured":"Lundberg C, Mart\u00ednez-Serrano A, Cattaneo E, McKay RD, Bj\u00f6rklund A. Survival, integration, and differentiation of neural stem cell lines after transplantation to the adult rat striatum. Exp Neurol. 1997;145(2 Pt 1):342\u201360.","journal-title":"Exp Neurol"},{"issue":"10","key":"3591_CR28","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1038\/nprot.2014.158","volume":"9","author":"MA Lancaster","year":"2014","unstructured":"Lancaster MA, Knoblich JA. Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc. 2014;9(10):2329\u201340.","journal-title":"Nat Protoc"},{"issue":"10","key":"3591_CR29","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.15252\/embj.201694700","volume":"36","author":"M Renner","year":"2017","unstructured":"Renner M, Lancaster MA, Bian S, Choi H, Ku T, Peer A, et al. Self-organized developmental patterning and differentiation in cerebral organoids. Embo j. 2017;36(10):1316\u201329.","journal-title":"Embo j"},{"issue":"5646","key":"3591_CR30","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.1090187","volume":"302","author":"G Mallucci","year":"2003","unstructured":"Mallucci G, Dickinson A, Linehan J, Kl\u00f6hn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science. 2003;302(5646):871\u20134.","journal-title":"Science"},{"issue":"29","key":"3591_CR31","doi-asserted-by":"publisher","first-page":"10238","DOI":"10.1073\/pnas.0802759105","volume":"105","author":"MD White","year":"2008","unstructured":"White MD, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci GR. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA. 2008;105(29):10238\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"3591_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219995","volume":"14","author":"H Bender","year":"2019","unstructured":"Bender H, Noyes N, Annis JL, Hitpas A, Mollnow L, Croak K, et al. PrPC knockdown by liposome-siRNA-peptide complexes (LSPCs) prolongs survival and normal behavior of prion-infected mice immunotolerant to treatment. PLoS ONE. 2019;14(7): e0219995.","journal-title":"PLoS ONE"},{"issue":"7","key":"3591_CR33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s10571-011-9696-z","volume":"31","author":"K Fujita","year":"2011","unstructured":"Fujita K, Yamaguchi Y, Mori T, Muramatsu N, Miyamoto T, Yano M, et al. Effects of a brain-engraftable microglial cell line expressing anti-prion scFv antibodies on survival times of mice infected with scrapie prions. Cell Mol Neurobiol. 2011;31(7):999\u20131008.","journal-title":"Cell Mol Neurobiol"},{"issue":"4","key":"3591_CR34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S1474-4422(22)00082-5","volume":"21","author":"S Mead","year":"2022","unstructured":"Mead S, Khalili-Shirazi A, Potter C, Mok T, Nihat A, Hyare H, et al. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurol. 2022;21(4):342\u201354.","journal-title":"Lancet Neurol"},{"issue":"6","key":"3591_CR35","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2174\/1574888X17666220823092202","volume":"18","author":"A Barmada","year":"2023","unstructured":"Barmada A, Sharan J, Band N, Rumschlag T, Yaqub A, Liebman E, et al. Review of the published literature confirms the safety of intravenous infusion of mesenchymal stem cells. Curr Stem Cell Res Ther. 2023;18(6):779\u201386.","journal-title":"Curr Stem Cell Res Ther"},{"issue":"10","key":"3591_CR36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.52586\/4980","volume":"26","author":"P Petrou","year":"2021","unstructured":"Petrou P, Kassis I, Yaghmour NE, Ginzberg A, Karussis D. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis. Front Biosci (Landmark Ed). 2021;26(10):693\u2013706.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"3591_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00441-022-03589-x","volume":"392","author":"RO Walters","year":"2023","unstructured":"Walters RO, Haigh CL. Organoids for modeling prion diseases. Cell Tissue Res. 2023;392(1):97\u2013111.","journal-title":"Cell Tissue Res"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03591-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-023-03591-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03591-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T12:12:48Z","timestamp":1701778368000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-023-03591-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3591"],"URL":"https:\/\/doi.org\/10.1186\/s13287-023-03591-2","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The human-induced pluripotent stem cells and brain homogenates used in this study were de-identified before being provided to the researchers at the NIH. Thus, the NIH Office of Human Subjects Research Protections (OHSRP) has determined these samples to be exempt from IRB review as per (1) Title of the approved project; Prion protein function in redox homeostasis and associated failure in prion disease. (2) Name of the institutional approval committee or unit; NIH Office of Human Subjects Research Protection (3) Approval number; 17-NIAID-00212 (4) Date of approval; 8\/3\/2017.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"348"}}